Esomeprazole Injection

Product/Composition Esomeprazole Injection
Strength 40mg
Form Injection
Production Capacity 1 Million Injection/Month
Therapeutic use GIT Medicine
Package Insert/Leaflet Available upon request

Esomeprazole Injection

  • Type: Acid-reducing medication

  • Drug Class: Proton Pump Inhibitor (PPI)

  • Form: Lyophilized powder or solution for intravenous (IV) injection or infusion

How It Works

  • Esomeprazole selectively inhibits the H⁺/K⁺ ATPase enzyme (proton pump) in the stomach lining.

  • This blocks the final step of gastric acid secretion, reducing stomach acid production regardless of stimulus (food, histamine, gastrin).

  • IV administration allows rapid acid suppression, which is useful when oral intake is not possible.

Common Uses

Esomeprazole injection is generally used for:

  • Acute treatment of gastric or duodenal ulcers, especially those associated with upper GI bleeding

  • Prevention of rebleeding after endoscopic treatment of peptic ulcers

  • Severe gastroesophageal reflux disease (GERD) when oral therapy is not feasible

  • Stress ulcer prophylaxis in critically ill patients

  • Treatment of Zollinger–Ellison syndrome (severe acid hypersecretion disorder) when oral therapy is not an option

Advantages

  • Works quickly to control stomach acid production

  • Suitable for patients who cannot swallow pills or are on nil per oral (NPO) status

  • Reduces risk of rebleeding in high-risk ulcer patients

  • Once stabilized, patients can be switched to oral PPI therapy

Possible Side Effects

Common:

  • Headache

  • Diarrhea or constipation

  • Nausea

  • Abdominal discomfort

Less Common but Serious:

  • Low magnesium levels (with prolonged use)

  • Rare allergic reactions (rash, swelling, breathing difficulty)

  • Very rarely, kidney inflammation (interstitial nephritis)

  • Risk of Clostridioides difficile infection with long-term use

Precautions

  • Use with caution in patients with severe liver disease (dose adjustment may be needed)

  • Long-term use should be monitored for risks like vitamin B12 deficiency or bone fractures

  • Should not be mixed with other IV medications in the same line unless compatibility is confirmed

  • Stop IV once the patient can tolerate oral medication and switch to oral PPI